Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNASDAQ:CTIC
Date3/1997
Raised
Post IPO Valuation

General Information

Websitebindtherapeutics.com
Twitter@BINDTx
CategoryBioTech
Phone617-491-3400
Emailinfo@bindtherapeu...
Employees
Founded2006

Offices

Cambridge, USA
325 Vassar Street
Cambridge, MA, 02139
USA

People

Founder & Board of Directors
Co-Founder
Chairman, Board of Directors
CFO
CSO
Chief Financial Officer
President & CEO
Vice President, Development
Show All People

Funding

TOTAL $117M
FUNDING TOTAL $46.6M
Series C, 6/2010
Polaris Partners
Flagship Ventures
ARCH Venture Partners
NanoDimension
$12.4M
Series D, 2/2012
RUSNANO
$25.5M
Partial Close, 2/2013
$8.7M
POST IPO FUNDING TOTAL $70.5M
Post IPO Equity, 9/2013
$70.5M
DEBT TOTAL $4.75M
Debt, 10/2011
$4.75M

Tags

BIND Therapeutics

They are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). To date in 2013, we have announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines.

Recent Milestones

Videos

Screenshots

BIND Therapeutics screenshot
Above: Homepage
Uploaded: 9/20/13

Stock Price

Sources

  1. Bind banks $12.4M round as lead program heads into PhI Read more: Bind banks $12.4M round as lead program heads into PhI - FierceBiotech http://www.fiercebiotech.com/story/bind-banks-12-4m-round-lead-program-heads-phi/2010-06-29?utm_medium=rss&utm_source (fiercebiotech.com) [edit]
  2. Bind Biosciences brings in $4.75M in debt funding (masshightech.com) [edit]
  3. Bind Biosciences, Inc.: Series D $25.5M (onbiovc.com) [edit]
  4. SEC (sec.gov) [edit]
  5. BIND Therapeutics raises $70.5M in IPO (boston.com) [edit]
  6. BIND Therapeutics Files for IPO (pevc.dowjones.com) [edit]
Edit This Page
Last Edited 1/31/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy